NexImmune to Present at 2021 SITC Annual Meeting
GAITHERSBURG, Md., Nov. 03, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that two abstracts have been accepted for poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting in Washington, D.C., being held November 10-14, 2021.
Poster Presentations:
- High throughput screening of HPV-antigen peptides and expansion of tumor-specific T cells for adoptive cell therapy of HPV-associated malignancies
- In vivo and in vitro characterization of AIM ACT, a novel nanoparticle-based technology, expanded MART-1 specific T cells